Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Medifast (MED) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Medifast (MED) over the last 16 years, with Q4 2025 value amounting to 10.39%.

  • Medifast's EBITDA Margin fell 109900.0% to 10.39% in Q4 2025 from the same period last year, while for Dec 2025 it was 3.68%, marking a year-over-year decrease of 41600.0%. This contributed to the annual value of 3.68% for FY2025, which is 41600.0% down from last year.
  • As of Q4 2025, Medifast's EBITDA Margin stood at 10.39%, which was down 109900.0% from 4.56% recorded in Q3 2025.
  • Over the past 5 years, Medifast's EBITDA Margin peaked at 15.58% during Q2 2021, and registered a low of 10.39% during Q4 2025.
  • Moreover, its 5-year median value for EBITDA Margin was 10.23% (2022), whereas its average is 6.57%.
  • In the last 5 years, Medifast's EBITDA Margin plummeted by -177400bps in 2024 and then surged by 36600bps in 2025.
  • Medifast's EBITDA Margin (Quarter) stood at 12.4% in 2021, then decreased by -22bps to 9.67% in 2022, then tumbled by -53bps to 4.54% in 2023, then crashed by -87bps to 0.6% in 2024, then crashed by -1844bps to 10.39% in 2025.
  • Its EBITDA Margin was 10.39% in Q4 2025, compared to 4.56% in Q3 2025 and 1.01% in Q2 2025.